
|Videos|October 1, 2015
Can Biosimilars Reduce Specialty Spending?
Author(s)Davy James, Managing Editor
David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.
Advertisement
David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FAQ: Guidance for Pharmacists, SSRIs Under Scrutiny and Political Debate
2
What Pharmacists Should Know About High-Dose Semaglutide’s Safety Profile
3
Ensitrelvir Demonstrates Significant COVID-19 Post-Exposure Prophylaxis Efficacy in Phase 3 Trial
4
How Advanced Technology Is Reshaping Medication Safety and Pharmacy Practice
5



































































































































